

1 **Title:**

2 **Ultrasound versus fluoroscopy as imaging guidance for percutaneous nephrolithotomy: A**
3 **systematic review and meta-analysis**

4 Razman Arabzadeh Bahri^{1,2*}, Saba maleki³, Arman Shafiee⁴, Parnian Shobeiri¹

5 ¹ School of Medicine, Tehran University of Medical Science, Tehran, Iran

6 ² Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

7 ³ School of Medicine, Guilan University of Medical Sciences (GUMS), Rasht, Guilan Province,
8 Iran

9 ⁴ Student Research Committee, School of Medicine, Alborz University of Medical Sciences,
10 Karaj, Iran

11 Corresponding author*

12 Email: raz_bahri@yahoo.com

13 **Abstract**

14 **Objectives:** To determine whether the outcomes of ultrasound-guided percutaneous
15 nephrolithotomy (UG-PCNL), an alternative to traditional fluoroscopy-guided percutaneous
16 nephrolithotomy (FG-PCNL), are comparable.

17 **Methods:** A systematic search of PubMed, Embase, and the Cochrane Library was carried out to
18 discover investigations comparing UG-PCNL to FG-PCNL, and accordingly, a meta-analysis of
19 those studies was performed. The primary outcomes included the stone-free rate (SFR), overall
20 complications based on Clavien-Dindo classification, duration of surgery, duration of patients'
21 hospitalization, and hemoglobin (Hb) drop during the surgery. All statistical analyses and
22 visualizations were implemented utilizing R software.

23 **Results:** Nineteen studies, including eight randomized clinical trials (RCTs) and eleven
24 observational cohorts, comprising 3016 patients (1521 UG-PCNL patients) and comparing UG-
25 PCNL with FG-PCNL met the inclusion criteria of the current study. Considering SFR, overall
26 complications, duration of surgery, duration of hospitalization, and Hb drop, our meta-analysis
27 revealed no statistically significant difference between UG-PCNL and FG-PCNL patients, with p-
28 values of 0.29, 0.47, 0.98, 0.28, and 0.42, respectively. Significant differences were discovered
29 between UG-PCNL and FG-PCNL patients in terms of the length of time they were exposed to
30 radiation (p-value< 0.0001). Moreover, FG-PCNL had shorter access time than UG-PCNL (p-
31 value= 0.04).

32 **Conclusion:** UG-PCNL provides the advantage of requiring less radiation exposure while being
33 just as efficient as FG-PCNL; thus, this study suggests prioritizing the use of UG-PCNL.

1 **Keywords:** Fluoroscopy - Ultrasonography - Nephrolithotomy - Percutaneous - Urinary calculi -
2 Meta-analysis

3

4 **Introduction**

5 Urolithiasis is a common urological disease with increasing prevalence (1). Percutaneous
6 nephrolithotomy (PCNL) is a minimally invasive procedure for removing complex or large kidney
7 stones (2, 3) and is conventionally performed under fluoroscopic guidance. A major concern
8 related to fluoroscopy-guided percutaneous nephrolithotomy (FG-PCNL) is the effect of exposure
9 to ionizing radiation by patients, surgeons, and operating room personnel (4, 5). Thus, an
10 alternative imaging technique for PCNL would be advantageous (6). To avoid radiation exposure,
11 some surgeons prefer ultrasound-guided percutaneous nephrolithotomy (UG-PCNL) (7). Given
12 the higher rate of availability of ultrasound (US) devices in most peripheral hospitals, the use of
13 UG-PCNL also increases the number of PCNL procedures. Also, the total cost of UG-PCNL is
14 30% less than that of FG-PCNL in every case (8). PCNL is performed in prone, supine, or flank
15 positions. The prone position is the preferred modality for creating percutaneous access and
16 localizing stones during FG-PCNL (9) although, in obese patients, it is not an ideal position(10).
17 UG-PCNL can also be performed in the flank or supine position with a lower risk of complications
18 during anesthesia(11). There have been various studies, including observational studies or clinical
19 trials, comparing the feasibility, safety, and efficacy of ultrasound-guided and fluoroscopy-guided
20 PCNL, but the conclusion has scarce available data and the choice between these modalities is
21 based on the preference of the urologist. Therefore, updating this data is mandatory. In addition,
22 there has not been a comprehensive assessment of randomized clinical trials (RCTs) and
23 observational cohort studies comparing UG-PCNL and FG-PCNL. Therefore, we aimed to
24 systematically review and conduct a meta-analysis to compare the efficacy of UG-PCNL with FG-
25 PCNL in different outcomes for the treatment of urolithiasis.

26 **Methods and materials**

27 This study was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-
28 Analyses (PRISMA) guidelines. The protocol of this study is registered in PROSPERO
29 (CRD42022327222)

1

2 **Search strategy**

3 A comprehensive search was conducted in international databases, including Cochrane library,
4 PubMed, and Embase, for relevant studies published from the inception to March 19th, 2022. The
5 search was conducted again for the determination of newly published and relevant studies one
6 week before the submission of the manuscript. The search keywords were categorized into three
7 groups: Ultrasound, fluoroscopy, and nephrolithotomy. In the ultrasound group, we used any
8 possible keywords such as ultrasound, US, ultrasound-guided, ultrasonography, and
9 ultrasonographic. In the fluoroscopy group, we used all possible keywords, including fluoroscopy,
10 X-ray, and fluoroscopic. In the nephrolithotomy group, the keywords used in the search strategy
11 were percutaneous nephrolithotomy, minimally invasive percutaneous nephrolithotomy, and
12 PCNL. The keywords were combined with “AND” between the groups, and with “OR” in each
13 group.

14

15 **Eligibility criteria**

16 The inclusion criteria for study selection were as follows: (a) patients with urolithiasis condition;
17 (b) comparison of ultrasound-guided PCNL and fluoroscopy-guided PCNL; (c) reporting of at
18 least SFR and complication rate, and (d) studies in the English language. The exclusion criteria for
19 study selection were as follows: (a) non-randomized studies, (b) Meta-analysis studies, and (c)
20 review studies. No limitation was imposed in this study for study sample sizes and patient
21 characteristics.

22 **Data extraction and quality assessment**

23 The initial screening of studies was carried out by two reviewers independently based on titles and
24 abstracts to exclude non-related studies. The full text of related studies was then reviewed for
25 confirmation of eligibility criteria meeting and data extraction. The data extraction of each study
26 using an Excel-based sheet were checked and discussed by two reviewers independently. The data
27 sheet included the first author names, type of studies, year of publications, number of patients in
28 ultrasound and fluoroscopy group, patients’ characteristics, SFRs, PCNL techniques, multiple
29 stone status, stone burden, hydronephrosis degree, ultrasound probe, sheath size, dilator,

1 complication rate, surgery time and Hb decrease after the surgery. The methodological quality of
2 the included studies was independently assessed by two reviewers using the national institute of
3 health (NIH) quality assessment tool for cohort studies and the risk of bias (RoB2) method of the
4 Cochrane Collaboration for RCTs.

5 **Outcomes**

6 Five primary outcomes and five secondary outcomes were evaluated and analyzed. The primary
7 outcomes included the SFRs, overall complications based on Clavien-Dindo classification,
8 duration of surgery, duration of patients' hospitalization, and hemoglobin (Hb) drop during the
9 surgery. The secondary outcomes included need for blood transfusion, fever after the surgery,
10 radiation exposure of the patients, time to access the stone, and the number of attempts by the
11 surgeon for the procedure.

12 **Statistical analysis**

13 The risk ratio (RR) was used to summarize the pooled effect size of dichotomous outcomes, and
14 the standardized mean difference (SMD) was used for reporting the results of continuous
15 outcomes. Study heterogeneity was assessed using the Chi-square test and I² statistic, with I²
16 values of <25% indicating a low amount of heterogeneity. A fixed effect meta-analysis was
17 performed in the case of low heterogeneity; otherwise, a random effect model was used. In order
18 to investigate any potential effects of the type of study, sub-group analysis was carried out based
19 on their design (whether a randomized controlled trial (RCT) or an observational cohort).
20 Publication bias was assessed using funnel plots and Egger's regression test for funnel plot
21 asymmetry. We did not report publication bias for outcomes with less than ten studies included. A
22 meta-regression was performed to investigate the possible association between the publication year
23 as a measure of clinicians' experience in performing US-guided PCNL and the effect size. Meta-
24 regression analyses were only done on primary outcomes. All statistical analyses and graphics
25 were carried out using R (version 4.1.3) (R Core Team, 2020) and the meta package.

26

27 **Results**

28 **Study Characteristics**

1 Nineteen studies, including eight RCTs and eleven observational cohorts comparing UG-PCNL
2 with FG-PCNL, were included in our study (Fig1). The characteristics of the included studies are
3 presented in Table1. The first study was published in 2008 and the majority of the studies have
4 been published in recent years (2016-2021). The sample size of the articles ranged from 45 to 906.
5 A total of 3016 patients were evaluated in the included studies (of which 1521 patients underwent
6 UG-PCNL)

7 **Primary outcomes**

8 **SFR**

9 Eighteen studies comprising 2815 patients (of which 1411 underwent UG-PCNL) were included
10 in our analysis (12-29). No significant differences were observed in the case of SFR between
11 ultrasound and fluoroscopy-guided patients (RR: 1.02; 95% CI: 0.98 to 1.06; $p = 0.29$; $I^2 = 46\%$)
12 (Fig. 2-A). Furthermore, no significant between-group differences were observed based on the
13 study design ($p = 0.75$). Our meta-regression analysis revealed no significant association between
14 publication year (as a measure of clinicians' experience) and risk of SFR ($p = 0.81$) (Fig. 5). Visual
15 inspection of the funnel plot revealed no possible source of small study effects (Fig. 3-A). This
16 was further confirmed by using the Eggers regression test for funnel plot asymmetry ($p = 0.40$).

17 **Overall complication**

18 For comparing the rate of complications between groups, studies reporting the outcome of the
19 Clavien-Dindo classification system were included in this analysis. Sixteen studies reported
20 compared complications based on this classification (13-24, 26-29). These studies included 1346
21 and 1339 patients treated with ultrasound and fluoroscopy-guided PCNL, respectively. Meta-
22 analysis of these studies revealed no significant difference in overall complication (RR: 0.88; 95%
23 CI: 0.62 to 1.25; $p = 0.47$; $I^2 = 62\%$) (Fig. 2-B). However, the results of our subgroup analysis
24 showed a significant reduction in the overall complication rate in the ultrasound-guided group
25 when pooling the results of RCTs independently (RR: 0.73; 95% CI: 0.59 to 0.90; $I^2 = 6\%$). No
26 significant association between publication year and complication was observed ($p = 0.80$) (Fig.
27 5). Visual inspection of the funnel plot revealed no possible source of small study effects (Fig. 3-
28 B). This was further confirmed by using the Eggers regression test for funnel plot asymmetry ($p =$
29 0.62).

1 **Duration of surgery**

2 Sixteen studies, including 2521 patients (of which 1264 underwent ultrasound-guided PCNL),
3 were included in our analysis (12, 14-24, 26-29). No significant differences were observed in
4 operation time between ultrasound and fluoroscopy-guided patients (SMD: 0.00; 95% CI: -0.39 to
5 0.39; $p = 0.98$; $I^2 = 89\%$) (Fig. 2-C). No significant between-group differences were observed
6 based on the study design ($p = 0.35$). Our meta-regression revealed a reduced SMD by increasing
7 publication year (as a measure of clinicians' experience) (Fig. 5). Although this interpretation was
8 made based on a non-significant result ($p = 0.37$). Visual inspection of the funnel plot revealed no
9 possible source of small study effects (Fig. 3-C). This was further confirmed by using the Eggers
10 regression test for funnel plot asymmetry ($p = 0.58$).

11 **Duration of hospitalization**

12 Sixteen studies comprising 2345 patients (of which 1126 underwent ultrasound-guided PCNL)
13 were included in our analysis (12, 14-24, 27-29). No significant differences were observed in
14 duration of hospitalization between ultrasound and fluoroscopy-guided patients (SMD: -0.09; 95%
15 CI: -0.27 to 0.08; $p = 0.28$; $I^2 = 81\%$) (Fig. 2-D). The pooled effect size from observational studies
16 showed a favorable outcome in ultrasound-guided patients (SMD: -0.17; 95% CI: -0.31 to -0.03;
17 $I^2 = 0\%$). Our meta-regression revealed a non-significant association between publication year and
18 duration of hospitalization ($p = 0.88$) (Fig. 5). Visual inspection of the funnel plot revealed the
19 presence of small study effects as an indication of publication bias (Fig. 3-D). This was further
20 confirmed by using the Eggers regression test for funnel plot asymmetry ($p = 0.001$).

21 **Hb drop**

22 Twelve studies comprising 2079 patients (of which 998 underwent ultrasound-guided PCNL) were
23 included (12, 14, 16-18, 20-22, 24, 27-29). Overall, no significant differences were observed in
24 Hb drop between ultrasound and fluoroscopy-guided patients after their operation (SMD: -0.07;
25 95% CI: -0.24 to 0.10; $p = 0.42$; $I^2 = 57\%$) (Fig. 2-E). The pooled results of RCTs showed a
26 favorable outcome in ultrasound-guided patients (SMD: -0.12; 95% CI: -0.22 to -0.01; $I^2 = 0\%$).
27 Our meta-regression revealed a non-significant association between publication year and duration
28 of hospitalization ($p = 0.41$) (Fig. 5). Visual inspection of the funnel plot revealed no possible

1 source of small study effects (Fig. 3-E). This was further confirmed by using the Eggers regression
2 test for funnel plot asymmetry ($p= 0.65$).

3 **Secondary outcomes**

4 **Need for blood transfusion**

5 Thirteen studies with 2238 patients (of which 998 underwent UG-PCNL) were included (12, 14,
6 15, 19-22, 24, 25, 27-30). Overall, no significant differences were observed in blood transfusion
7 rate between ultrasound and fluoroscopy-guided patients (RR: 0.77; 95% CI: 0.44 to 1.36; $p =$
8 0.37; $I^2 = 51\%$) (Fig. 4-A). The pooled results of RCTs showed a reduced need for blood
9 transfusion in ultrasound-guided patients (RR: 0.42; 95% CI: 0.27 to 0.64; $I^2 = 10\%$). Visual
10 inspection of the funnel plot revealed no possible source of small study effects (Fig. 3-F). This was
11 further confirmed by using the Eggers regression test for funnel plot asymmetry ($p= 0.55$).

12 **Fever**

13 Twelve studies with 2103 patients (of which 1010 underwent UG- PCNL) were included (12, 14,
14 15, 18, 21-25, 27-29). No significant differences were observed between ultrasound and
15 fluoroscopy-guided patients (RR: 0.97; 95% CI: 0.67 to 1.40; $p = 0.87$; $I^2 = 39\%$) (Fig. 4-B). Our
16 subgroup analysis showed no significant differences between the results of RCTs and
17 observational studies (Between groups $p= 0.36$). Visual inspection of the funnel plot revealed no
18 possible source of small study effects (Fig. 3-G). This was further confirmed by using the Eggers
19 regression test for funnel plot asymmetry ($p= 0.17$).

20 **Radiation exposure**

21 Seven studies comprising 811 patients (of which 386 underwent UG- PCNL) were included (13,
22 15-17, 20, 28, 30). When comparing the duration for which patients were exposed to radiation,
23 significant differences between ultrasound-guided patients and fluoroscopy-guided patients were
24 found. (SMD: -1.54; 95% CI: -2.29 to -0.79; $p < 0.0001$; $I^2 = 94\%$) (Fig. 4-C).

25 **Access time**

26 Six studies, including 664 patients (of which 330 underwent UG-PCNL), were included (12, 18,
27 19, 24, 29, 30). Our analysis revealed a shorter time needed for having access through the
28 fluoroscopy-guided technique. (SMD: 0.85; 95% CI: 0.04 to 1.66; $p= 0.04$; $I^2 = 95\%$) (Fig. 4-D).

1 **Number of attempts**

2 Three studies, including 368 patients (of which 184 underwent UG-PCNL), were included (13, 16,
3 27). No significant differences were observed between ultrasound and fluoroscopy-guided patients
4 (SMD: -0.51; 95% CI: -2.18 to 1.16; p= 0.54; I2 = 98%) (Fig. 4-E).

5 **Discussion**

6 To remove the renal stones, PCNL is offered with the highest SFR alongside high
7 complication(31). SFR is defined as the absence of residual stones, or the presence of residual
8 stone fragments less than 4 mm in size in follow-up studies such as kidney ultrasound and non-
9 contrast computed tomography (CT) (32).

10 The indications for PCNL are stones larger than 20 mm, staghorn, and partial staghorn calculi(33).
11 The contraindications for PCNL include pregnancy, bleeding disorders, and uncontrolled urinary
12 tract infections(34).

13 PCNL is an efficient technique for removing large and complex stones with high success and low
14 morbidity rates(35). PCNL is performed by making a small incision in the flank area under
15 fluoroscopy or ultrasound guidance(36). PCNL under ultrasound guidance has some advantages,
16 including the absence of ionizing radiation, shorter time of the procedure, less puncture, and no
17 more use of contrast agents(37-39). To decrease complications like blood loss, postoperative pain,
18 and renal damage due to larger instruments, a modification of the standard procedure was
19 propounded (41). In fluoroscopy-guided PCNL, contrast is injected through a urethral catheter.
20 Puncture failure and re-do FG-PCNL can be mentioned as a disadvantage of this procedure(40,
21 41). Some studies mention that UG-PCNL in the flank or the prone position has a higher success
22 rate and fewer complications compared with FG-PCNL(7, 42). In addition, mini-PCNL is a
23 standard technique in the treatment of renal and upper ureteric stones using a 28–30 F
24 ureteroscope(43).

25 In 2018, Yu-Hsiang and his colleagues published a meta-analysis comparing UG-PCNL with FG-
26 PCNL(44). It had eight included articles, and based on their analysis, they reported that UG-PCNL
27 had a significantly lower complication rate and also fewer intraoperative complications than FG-
28 PCNL(45, 46). Accordingly, UG-PCNL was also associated with reduced inadvertent organ injury
29 risks. Therefore, it can be concluded that ultrasound provides information about the surrounding

1 viscera, determines the depth of needle penetration, and identifies the area posterior to the anterior
2 calyces when comparing the different complication rates(47). Due to its analysis, UG-PCNL in the
3 supine position had a higher SFR and significantly lower complication rate than FG-PCNL in the
4 supine position. According to its results, it did not imply statistically significant differences in
5 SFR. however, it mentioned if a patient is an appropriate case for a supine position PCNL, like
6 patients with cardiovascular disease or spinal deformities, UG-PCNL can be a better choice than
7 FG-PCNL(11, 48). In mini-PCNL, they perform with a smaller percutaneous tract by using a
8 miniature endoscope. Accordingly, mini-PCNL was associated with less bleeding and
9 postoperative pain during the procedure(49, 50).

10 We conducted a systematic review and meta-analysis of efficacy and safety in UG-PCNL versus
11 FG-PCNL with 19 articles included. This study was the first meta-analysis to evaluate ultrasound
12 versus fluoroscopy as imaging guidance for percutaneous nephrolithotomy, including RCTs and
13 observational Cohort studies. The sample size of the articles ranged from 45 to 906. A total of
14 3016 patients were evaluated in the included studies (of which 1521 patients underwent UG-
15 PCNL). A regression analysis was done based on publication year and approaching recent years,
16 with increasing experience in performing UG-PCNL. A better result was seen than FG-PCNL.
17 Outcomes were considered in this meta-analysis in two groups. Each group had five sub-groups.
18 Primary outcomes included SFR, overall complications, duration of surgery, duration of
19 hospitalization, and Hb drop. Secondary outcomes considered the need for blood transfusion,
20 fever, radiation exposure, access time, and the number of attempts. In most outcomes except
21 radiation exposure and access time, no significant differences were observed between ultrasound
22 and fluoroscopy-guided studies. Based on our analysis, RCT studies presented fewer complication
23 rates compared to Cohort studies. In summary, comparing the results of this study to the systematic
24 review and meta-analysis published in 2018, most outcomes did not display significant differences.
25 Generally, between these two methods considered in this study, the results were in favor of UG-
26 PCNL.

27 **Limitations**

28 There are multiple reasons for the heterogeneity of the included studies and also the conflicting
29 results. On the one hand, the patients had different baseline characteristics, including body mass
30 index and hydronephrosis degree. On the other hand, the procedure was conducted in various

1 positions. In addition, ultrasound is operator-dependent, and its practicality is based on machine
2 properties and operator expertise.

3 **Conclusion**

4 According to the less radiation exposure when using the UG-PCNL technique, we suggest
5 prioritizing the utilization of UG-PCNL in treating renal stones. Regarding the fact that the
6 experience and level of expertise of the ultrasound performer may affect the findings, it is
7 recommended to prepare a program to train people who perform the procedure. This could reduce
8 the errors, which are mainly due to the lack of organized training programs and sufficient skills.

9 **Acknowledgments**

10 We thank all the authors of the included studies and all those who contributed to the present study.

11 **Author Contributions**

12 **Conceptualization:** Razman Arabzadeh Bahri.

13 **Data curation:** Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee.

14 **Formal analysis:** Arman Shafiee.

15 **Investigation:** Razman Arabzadeh Bahri, Saba Maleki.

16 **Methodology:** Arman Shafiee.

17 **Supervision:** Parnian Shobeiri.

18 **Visualization:** Razman Arabzadeh Bahri.

19 **Writing – original draft:** Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee.

20 **Writing – review & editing:** Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee, Parnian
21 Shobeiri.

22

23

24

25

26

27

28

29

1

- 2 1. Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. *Investigative and clinical*
3 *urology*. 2017;58(5):299-306.
- 4 2. Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU guidelines on interventional
5 treatment for urolithiasis. *European urology*. 2016;69(3):475-82.
- 6 3. Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al. Surgical management
7 of stones: American urological association/endourological society guideline, PART I. *The Journal of*
8 *urology*. 2016;196(4):1153-60.
- 9 4. Hidajat N, Wust P, Kreuschner M, Felix R, Schroder R. Radiation risks for the radiologist
10 performing transjugular intrahepatic portosystemic shunt (TIPS). *The British Journal of Radiology*.
11 2006;79(942):483-6.
- 12 5. Vano E, Kleiman NJ, Duran A, Romano-Miller M, Rehani MM. Radiation-associated lens opacities
13 in catheterization personnel: results of a survey and direct assessments. *Journal of Vascular and*
14 *Interventional Radiology*. 2013;24(2):197-204.
- 15 6. Mancini JG, Raymundo EM, Lipkin M, Zilberman D, Yong D, Bañez LL, et al. Factors affecting
16 patient radiation exposure during percutaneous nephrolithotomy. *The Journal of urology*.
17 2010;184(6):2373-7.
- 18 7. Hosseini MM, Hassanpour A, Farzan R, Yousefi A, Afrasiabi MA. Ultrasonography-guided
19 percutaneous nephrolithotomy. *Journal of endourology*. 2009;23(4):603-7.
- 20 8. Hudnall M, Usawachintachit M, Metzler I, Tzou DT, Harrison B, Lobo E, et al. Ultrasound
21 guidance reduces percutaneous nephrolithotomy cost compared to fluoroscopy. *Urology*. 2017;103:52-
22 8.
- 23 9. Ahmad AA, Alhunaidi O, Aziz M, Omar M, Al-Kandari AM, El-Nahas A, et al. Current trends in
24 percutaneous nephrolithotomy: an internet-based survey. *Therapeutic Advances in Urology*. 2017;9(9-
25 10):219-26.
- 26 10. Kwee MM, Ho Y-H, Rozen WM. The prone position during surgery and its complications: a
27 systematic review and evidence-based guidelines. *International surgery*. 2015;100(2):292-303.
- 28 11. Karaolides T, Moraitis K, Bach C, Masood J, Buchholz N. Positions for percutaneous
29 nephrolithotomy: Thirty-five years of evolution. *Arab Journal of Urology*. 2012;10(3):307-16.
- 30 12. Karami H, Rezaei A, Mohammadhosseini M, Javanmard B, Mazloomfard M, Lotfi B.
31 Ultrasonography-guided percutaneous nephrolithotomy in the flank position versus fluoroscopy-guided
32 percutaneous nephrolithotomy in the prone position: a comparative study. *J Endourol*. 2010;24(8):1357-
33 61.
- 34 13. Agarwal M, Agrawal MS, Jaiswal A, Kumar D, Yadav H, Lavania P. Safety and efficacy of
35 ultrasonography as an adjunct to fluoroscopy for renal access in percutaneous nephrolithotomy (PCNL).
36 *BJU Int*. 2011;108(8):1346-9.
- 37 14. Andonian S, Scoffone CM, Louie MK, Gross AJ, Grabe M, Daels FP, et al. Does imaging modality
38 used for percutaneous renal access make a difference? A matched case analysis. *J Endourol*.
39 2013;27(1):24-8.
- 40 15. Basiri A, Mirjalili MA, Kardoust Parizi M, Moosa Nejad NA. Supplementary X-ray for ultrasound-
41 guided percutaneous nephrolithotomy in supine position versus standard technique: a randomized
42 controlled trial. *Urol Int*. 2013;90(4):399-404.
- 43 16. Jagtap J, Mishra S, Bhattu A, Ganpule A, Sabnis R, Desai MR. Which is the preferred modality of
44 renal access for a trainee urologist: ultrasonography or fluoroscopy? Results of a prospective
45 randomized trial. *J Endourol*. 2014;28(12):1464-9.
- 46 17. Chi T, Masic S, Li J, Usawachintachit M. Ultrasound Guidance for Renal Tract Access and Dilation
47 Reduces Radiation Exposure during Percutaneous Nephrolithotomy. *Adv Urol*. 2016;2016:3840697.

- 1 18. Falahatkar S, Allahkhah A, Kazemzadeh M, Enshaei A, Shakiba M, Moghaddas F. Complete
2 supine PCNL: ultrasound vs. fluoroscopic guided: a randomized clinical trial. *Int Braz J Urol*.
3 2016;42(4):710-6.
- 4 19. Hamdy>Aboutaleb M, Mohammed El-Shazly MJAS. Ultrasound versus fluoroscopy guided
5 percutaneous nephrolithotomy for treatment of calculi in hydronephrotic kidneys. 2016;2:015.
- 6 20. Usawachintachit M, Masic S, Chang HC, Allen IE, Chi T. Ultrasound Guidance to Assist
7 Percutaneous Nephrolithotomy Reduces Radiation Exposure in Obese Patients. *Urology*. 2016;98:32-8.
- 8 21. Ng FC, Yam WL, Lim TYB, Teo JK, Ng KK, Lim SK. Ultrasound-guided percutaneous
9 nephrolithotomy: Advantages and limitations. *Investig Clin Urol*. 2017;58(5):346-52.
- 10 22. Sun H, Zhang Z, Huang G, Wan SP, Chen H, He B, et al. Fluoroscopy versus ultrasonography
11 guided mini-percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney
12 disease. *Urolithiasis*. 2017;45(3):297-303.
- 13 23. Sun W, Liu MN, Yang ZW, Wang Q, Xu Y. Ultrasound-guided percutaneous nephrolithotomy for
14 the treatment in patients with kidney stones. *Medicine (Baltimore)*. 2017;96(51):e9232.
- 15 24. Zhu W, Li J, Yuan J, Liu Y, Wan SP, Liu G, et al. A prospective and randomised trial comparing
16 fluoroscopic, total ultrasonographic, and combined guidance for renal access in mini-percutaneous
17 nephrolithotomy. *BJU Int*. 2017;119(4):612-8.
- 18 25. Abed SM, Alhamdani NJIJMS, 18. Ultrasonographic guidance versus fluoroscopic guidance for
19 renal access in percutaneous nephrolithotomy (PCNL): a comparative study. 2019;335.
- 20 26. Armas-Phan M, Tzou DT, Bayne DB, Wiener SV, Stoller ML, Chi T. Ultrasound guidance can be
21 used safely for renal tract dilatation during percutaneous nephrolithotomy. *BJU Int*. 2020;125(2):284-91.
- 22 27. Birowo P, Raharja PAR, Putra HWK, Rustandi R, Atmoko W, Rasyid N. X-ray-free ultrasound-
23 guided versus fluoroscopy-guided percutaneous nephrolithotomy: a comparative study with historical
24 control. *Int Urol Nephrol*. 2020;52(12):2253-9.
- 25 28. Sahan A, Cubuk A, Ozkaptan O, Ertas K, Canakci C, Eryildirim B, et al. Safety of Upper Pole
26 Puncture in Percutaneous Nephrolithotomy with the Guidance of Ultrasonography versus Fluoroscopy:
27 A Comparative Study. *Urol Int*. 2020;104(9-10):769-74.
- 28 29. Eslahi A, Ahmed F, Hosseini MM, Rezaeimehr MR, Fathi N, Nikbakht HA, et al. Minimal invasive
29 percutaneous nephrolithotomy (Mini-PCNL) in children: Ultrasound versus fluoroscopic guidance. *Arch
30 Ital Urol Androl*. 2021;93(2):173-7.
- 31 30. Basiri A, Ziaee AM, Kianian HR, Mehrabi S, Karami H, Moghaddam SM. Ultrasonographic versus
32 fluoroscopic access for percutaneous nephrolithotomy: a randomized clinical trial. *J Endourol*.
33 2008;22(2):281-4.
- 34 31. Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al. Surgical management
35 of stones: American urological association/endourological society guideline, PART I. 2016;196(4):1153-
36 60.
- 37 32. Atis G, Culpan M, Pelit ES, Canakci C, Ulus I, Gunaydin B, et al. Comparison of Percutaneous
38 Nephrolithotomy and Retrograde Intrarenal Surgery in Treating 20-40 mm Renal Stones. *Urol J*.
39 2017;14(2):2995-9.
- 40 33. Desai M, Sun Y, Buchholz N, Fuller A, Matsuda T, Matlaga B, et al. Treatment selection for
41 urolithiasis: percutaneous nephrolithomy, ureteroscopy, shock wave lithotripsy, and active monitoring.
42 *World journal of urology*. 2017;35(9):1395-9.
- 43 34. Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Wolf JS. Chapter 1: AUA
44 guideline on management of staghorn calculi: diagnosis and treatment recommendations. *The Journal
45 of urology*. 2005;173(6):1991-2000.
- 46 35. Sun W, Liu M-n, Yang Z-w, Wang Q, Xu Y. Ultrasound-guided percutaneous nephrolithotomy for
47 the treatment in patients with kidney stones. *Medicine*. 2017;96(51).

- 1 36. Fernström I, Johansson B. Percutaneous pyelolithotomy: a new extraction technique.
2 Scandinavian journal of urology and nephrology. 1976;10(3):257-9.
- 3 37. Zegel H, Pollack H, Banner M, Goldberg B, Arger P, Mulhern C, et al. Percutaneous nephrostomy:
4 comparison of sonographic and fluoroscopic guidance. American Journal of Roentgenology.
5 1981;137(5):925-7.
- 6 38. Basiri A, Ziaee SAM, Nasseh H, Kamranmanesh M, Masoudy P, Heidary F, et al. Totally
7 ultrasonography-guided percutaneous nephrolithotomy in the flank position. Journal of endourology.
8 2008;22(7):1453-8.
- 9 39. Gupta S, Gulati M, Suri S. Ultrasound-guided percutaneous nephrostomy in non-dilated
10 pelvicaliceal system. Journal of clinical ultrasound. 1998;26(3):177-9.
- 11 40. HamdyAboutaleb M, Mohammed El-Shazly M. Ultrasound versus fluoroscopy guided
12 percutaneous nephrolithotomy for treatment of calculi in hydronephrotic kidneys. Ann SurgInt.
13 2016;2:015.
- 14 41. Inanloo SH, Yahyazadeh SR, Rashidi S, Amini E, Nowroozi MR, Ayayti M, et al. Feasibility and
15 safety of ultrasonography guidance and flank position during percutaneous nephrolithotomy.
16 2018;200(1):195-201.
- 17 42. Basiri A, Ziaee AM, Kianian HR, Mehrabi S, Karami H, Moghaddam SMH. Ultrasonographic versus
18 fluoroscopic access for percutaneous nephrolithotomy: a randomized clinical trial. Journal of
19 endourology. 2008;22(2):281-4.
- 20 43. Desai J, Zeng G, Zhao Z, Zhong W, Chen W, Wu W. A novel technique of ultra-mini-percutaneous
21 nephrolithotomy: introduction and an initial experience for treatment of upper urinary calculi less than
22 2 cm. BioMed research international. 2013;2013.
- 23 44. Yang Y-H, Wen Y-C, Chen K-C, Chen C. Ultrasound-guided versus fluoroscopy-guided
24 percutaneous nephrolithotomy: a systematic review and meta-analysis. World journal of urology.
25 2019;37(5):777-88.
- 26 45. Ng FC, Yam WL, Lim TYB, Teo JK, Ng KK, Lim SK. Ultrasound-guided percutaneous
27 nephrolithotomy: advantages and limitations. Investigative and clinical urology. 2017;58(5):346-52.
- 28 46. Wang K, Zhang P, Xu X, Fan M. Ultrasonographic versus fluoroscopic access for percutaneous
29 nephrolithotomy: a meta-analysis. Urologia internationalis. 2015;95(1):15-25.
- 30 47. Lojanapiwat B. The ideal puncture approach for PCNL: Fluoroscopy, ultrasound or endoscopy?
31 Indian journal of urology: IJU: journal of the Urological Society of India. 2013;29(3):208.
- 32 48. Manohar T, Jain P, Desai M. Supine percutaneous nephrolithotomy: effective approach to high-
33 risk and morbidly obese patients. Journal of endourology. 2007;21(1):44-9.
- 34 49. Jackman SV, Docimo SG, Cadeddu JA, Bishoff JT, Kavoussi LR, Jarrett TW. The “mini-perc”
35 technique: a less invasive alternative to percutaneous nephrolithotomy. World journal of urology.
36 1998;16(6):371-4.
- 37 50. Haghghi R, Zeraati H, Zade MG. Ultra-mini-percutaneous nephrolithotomy (PCNL) versus
38 standard PCNL: A randomised clinical trial. Arab Journal of Urology. 2017;15(4):294-8.

39

40






Fig. 1: PRISMA flowchart of the literature search and selection of the articles.

(A) Stone-free rate





medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

(B) Overall complications



(C) Duration of surgery







medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Fig. 2: Forest plots of primary outcomes of UG-PCNL (experimental) versus FG-PCNL (control)


(A) Stone-free rate




(B) Overall complications



(C) Duration of surgery




(D) Duration of hospitalization




medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

(E) Hemoglobin drop



(F) Need for blood transfusion



(G) Fever






Fig. 3 Funnel plots of outcomes reported in at least 10 studies

(A) Need for blood transfusion




medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


(B) Fever



(C) Radiation exposure



(D) Access time



medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

(E) Number of attempts






Fig. 4 Forest plots of secondary outcomes of UG-PCNL (experimental) versus FG-PCNL (control)

(A) Stone-free rate





medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

(B) Overall complications



(C) Duration of surgery





medRxiv preprint doi: <https://doi.org/10.1101/2022.10.13.22281046>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Fig. 5 Results of meta-regression. Effects of publication year and the experience of the clinician on primary outcomes

Table 1. Characteristics of Included Studies

First Author	Type of Study	Cases (UG/FG)	Mean Age (UG/FG)	Sex Male n(UG/FG)	Mean BMI (UG/FG)	SFR (%)	PCNL Technique	Multiple Stones	Stone Location (UG/FG)	Stone Burden	Hydronephrosis Degree	Ultrasound Probe	Sheath Size	Dilator
Basiri et al., 2008	RCT	50/50	40.7/41.6	34/31	25/24.6	N/A	Flank: 100/100	0/0	Inferior: 40/40 Middle: 7/9 Superior: 3/1	24/27	Mild: 28/32 - Moderate: 40/42 - Severe: 32/26	3.5 MHz	30 F	Amplatz
Karami et al., 2010	RCT	30/30	40.9/39.4	18/19	27.8/26	86.6/90	Flank/Prone	0/0	Superior calyx: 3/2 Middle calyx: 7/7 Inferior calyx: 14/17 Renal pelvis: 6/4	28.7/27.4	Mild: 40/46 - Moderate: 53/36 - Severe: 6/16	3.5 MHz	28-30 F	Amplatz
Agarwal et al., 2011	RCT	112/112	31/35	N/A	N/A	100/100	Prone: 100/100	N/A	N/A	280/230mm ²	N/A	3.5 MHz	26-28 F	Amplatz
Andonian et al., 2013	Cohort	453/453	50.2/47.9	62.5%/37.5%	N/A	79.8/73.5	Prone: 93.8/84.1 - Supine: 6.2/15.9	56.3/67.5	Upper calyx: 8.9/8.8 Middle calyx: 39.2/11.1 Lower calyx: 44.8/68.1 Multiple calyces: 7.1/11.9	349/456.6	N/A	N/A	22.6/29.5	Balloon: 9.9/58.7 - Telescopic: 90.2/41.2
Basiri et al., 2013	RCT	43/46	45.7/44.8	30/31	25.29/24.86	73.9/65.2	Supine/Prone	30/43	Renal pelvis: 16/15 Inferior calyx: 10/8 Middle calyx: 4/3 Renal pelvis + inferior calyx: 7/10 Renal pelvis + middle calyx: 1/8 Middle and inferior calices: 5/2	N/A	N/A	3.5 MHz	28-30 F	Amplatz
Jagtap et al., 2014	RCT	32/32	40.7/44.5	25/20	N/A	100/100	Prone: 100/100	9/6	Superior calyx: 3/2 Middle calyx: 3/7 Inferior calyx: 10/10 Renal pelvis: 13/11	21/22	Mild: 40/46 - Moderate: 34/31 - Severe: 6/6	3.5 MHz	28 F	Amplatz
Falahatkar et al., 2016	RCT	26/25	48.41/51.17	17/15	28.14/26.31	76.9/68	Supine: 100/100	N/A	N/A	26.48/30.44	N/A	N/A	N/A	Amplatz
Chi et al., 2016	Cohort	38/38	52.7/52.9	17/19	26.1/30.3	100/89.4	Prone: 100/100	18.4/5.3	Calyceal: 12(31.6)/9(23.7) Renal pelvis: 10(26.3)/14(36.8) Proximal urethral: 3(7.9)/7(18.4)	N/A	Mild: 21.1/24.2 - Moderate: 21.1/21.1 - Severe: 5.2/5.2	N/A	24-30 F	Balloon
Sun et al., 2016	Retrospective Cohort	20/25	49.2/47.3	14/17	24.5/22.8	92.8/95.8	Prone: 100/100	60/56	Pelvis or proximal urether: 4/5	N/A	None or mild: 40/60 - Moderate or Severe: 60/40	N/A	18 F	N/A
Hamdy et al., 2016	Retrospective Cohort	42/49	40.2/43	35/39	N/A	80/83.7	Prone: 100/100	N/A	N/A	N/A	Mild: 33.3/77.5 - Moderate: 23.8/18.3 - Severe: 42.8/4	3.5-5 MHz	30 F	Amplatz
Usawa et al., 2016	Cohort	93/42	51.7/54.4	38/15	28.7/30.4	77.4/83.4	Prone: 100/100	16.1/7.1	Calyceal: 22(23.7)/12(28.6) Pelvic: 23(24.7)/11(26.2)	N/A	Mild: 34.4/28.6 - Moderate: 16.1/21.4 - Severe: 6.5/4.8	3.5 MHz	N/A	N/A
Ng et al., 2017	Cohort	72/112	55.6/52.6	50/87	N/A	66.7/43.7	Prone: 100/100	N/A	N/A	N/A	Mild: 44.4/37.5 - Moderate: 18.1/23.2 - Severe: 15.3/16.1	N/A	30 F	Amplatz
Sun et al., 2017	RCT	43/43	42.9/45.1	29/32	24.2/24.5	79.1/69.8	Supine: 100/100	N/A	Renal pelvis: 15/17 Inferior calyx: 11/10 Middle calyx: 5/4 Renal pelvis + inferior calyx: 7/6	29.4/30.1	N/A	3.5 MHz	30 F	Amplatz

First Author	Type of Study	Cases (UG/FG)	Mean Age (UG/FG)	Sex Male n(UG/FG)	Mean BMI (UG/FG)	SFR (%)	PCNL Technique	Multiple Stones	Stone Location (UG/FG)	Stone Burden	Hydronephrosis Degree	Ultrasound Probe	Sheath Size	Dilator
									Renal pelvis + middle calyx: 1/3 Middle and inferior callices:4/3					
Zhu et al., 2017	RCT	147/145	49.9/49.6	86/77	23.7/23.5	55.1/62.8	Prone: 100/100	89/84	Superior calyx: 44/46 Middle calyx: 92/74 Inferior calyx: 26/59	838.3/834.8 mm ²	None or mild: 59/64.8 - Moderate or Severe: 40.8/35	N/A	18 F	N/A
Armas-phan et al., 2018	Cohort	138/38	54.6/51	63/18	28.8/30.1	57/56	Prone: 71/29	N/A	N/A	30/32	Yes (n) : 65/15	N/A	24 F	Balloon
Abed et al., 2019	Cohort	35/35	N/A	18/20	N/A	62.9/80	Prone: 100/100	N/A	N/A	N/A		N/A	26 F	Amplatz
Sahan et al., 2020	Retrospective Cohort	72/105	49.2/48.3	34/26	N/A	75/77.1	Prone: 100/100	36.7/45.7	Upper calyx: 28(38.9)/23(21.9)	N/A	None or mild: 30.6/40.9 - Moderate or Severe: 69.4/59.1	N/A	26 F	Amplatz
Birowo et al., 2020	Cohort	40/80	49.2/54.3	17/47	25.3/25	85/75	Prone: 0/50	40/55	N/A	27.5/34.25	Yes: 50/38.75	N/A	28-30 F	Amplatz
Eslahi et al., 2021	Cohort	35/35	5.68/7.47	25/23	N/A	97.1/94.3	Prone: 100/100		N/A	15.94/19.2	Mild: 57.1/51.4 - Moderate: 34.3/37.1 - Severe: 8.6/11.4	3.5 MHz	15 F	Amplatz

Abbreviations: UG: Ultrasound-guided; FG: Fluoroscopy-guided; RCT: Randomized Clinical Trial; BMI: Body mass index; SFR: Stone-free rate; PCNL: Percutaneous Nephrolithotomy